1. Scrip
  2. >>Business

Hunger Game: Hengrui Hunts New Cancer Drug With $200m BeyondSpring Tie-up

 
• By Dexter Jie Yan

Hengrui’s second major in-licensing deal this year is the latest example of the Chinese pharma innovation darling’s eagerness for new assets, particularly as some of its other products come under pressure.

Hengrui Medicine's deal with BeyondSpring
Hengrui Medicine went on a shopping spree in 2021. • Source: Alamy

Jiangsu Hengrui Medicine Co., Ltd. has gone on a shopping spree for new drug candidates as the Chinese domestic pharma heavyweight finds itself in a drought for novel drugs.

The latest deal saw Hengrui dole out CNY200m ($31m) in upfront payment to obtain exclusive commercial and co-development rights in Greater China (China, Hong Kong, Macau and Taiwan) to Shanghai-based...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.